ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2017
Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Criteria for Hyponatremic Overcorrection: Systematic Review and Cohort Study of Emergently Ill Patients.Journal of general internal medicine · 2020Pooled it
- Ribosomal s6 kinase is a mediator of aquaporin-2 S256 phosphorylation and membrane accumulation after EGFR inhibition with erlotinib.American journal of physiology. Renal physiology · 2025Article
- Case report: Secondary failure to tolvaptan in a patient with SCLC and paraneoplastic SIADH.Frontiers in endocrinology · 2024Article
- Safety and Efficacy of Vaptans in the Treatment of Hyponatremia from Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2023Review
- Inappropriate therapy of euvolemic hyponatremia, the most frequent type of hyponatremia in SARS-CoV-2 infection, is associated with increased mortality in COVID-19 patients.Frontiers in endocrinology · 2023Article
- Approach to the Patient: "Utility of the Copeptin Assay".The Journal of clinical endocrinology and metabolism · 2022Article
- Hyponatraemia and the syndrome of inappropriate antidiuresis (SIAD) in cancer.Endocrine oncology (Bristol, England) · 2022Review
- Multimodal Strategies for the Diagnosis and Management of Refractory Congestion. An Integrated Cardiorenal Approach.Frontiers in physiology · 2022Review
- Electrolyte Abnormalities Associated With the Use of Atezolizumab - A Systematic Review.Journal of community hospital internal medicine perspectives · 2022Review
- The role of tolvaptan in managing hyponatremia in small cell lung cancer patients with SIADH: a retrospective study of 23 cases.Translational cancer research · 2021Article
- Supportive Care: An Indispensable Component of Modern Oncology.Clinical oncology (Royal College of Radiologists (Great Britain)) · 2020Review
- Article
- Copeptin is not useful as a marker of malignant disease in the syndrome of inappropriate antidiuresis.Endocrine connections · 2020Article
- Vasopressin and Copeptin in health and disease.Reviews in endocrine & metabolic disorders · 2019Review
- Copeptin and its role in the diagnosis of diabetes insipidus and the syndrome of inappropriate antidiuresis.Clinical endocrinology · 2019Review
- Tolvaptan corrects hyponatremia and relieves the burden of fluid/dietary restriction and hospitalization in hyponatremic patients with terminal lung cancer: a report of two cases.CEN case reports · 2019Article
- Vasopressin Receptor Antagonists in Hyponatremia: Uses and Misuses.Frontiers in medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHyponatremia secondary to SIADH is frequent in cancer patients and potentially deleterious. The aim of this sub-analysis of the Hyponatremia Registry database is to analyze current diagnostic and therapeutic management practices in cancer patients with SIADH.
methodsWe analyzed 358 cancer patients who had serum sodium concentration ([Na
resultsPrecise diagnostic testing was performed in only 46%. Almost 12% of all patients did not receive any hyponatremia treatment. The most frequent therapies were fluid restriction (20%), isotonic saline (14%), fluid restriction/isotonic saline (7%), tolvaptan (8%), and salt tablets (7%). Hypertonic saline was used in less than 3%. Tolvaptan produced the greatest median rate of [Na
conclusionsAlthough essential for successful hyponatremia management, appropriate diagnostic testing is not routinely performed in current practice. The most frequently employed monotherapies were often ineffective and sometimes even aggravated hyponatremia. Tolvaptan was used less often but showed significantly greater effectiveness. Despite clear evidence that hyponatremia is associated with poor outcome in oncology patients, most patients were discharged still hyponatremic. Further studies are needed to assess the beneficial impact of hyponatremia correction with effective therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.